In a study, blocking the immune system complement protein C3 was shown to reduce MS disease severity in older mice but not in ...
The investigational therapy fenebrutinib was as effective as Ocrevus for reducing disability progression in people with PPMS, a trial showed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results